Loading
A phase 2 trial of IMC-001 in peripheral T-cell lymphomas, run by ImmuneOncia Therapeutics Inc., active and no longer recruiting.
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type is a phase 2 interventional study registered as NCT04414163 by ImmuneOncia Therapeutics Inc., with 23 participants enrolled, started 2020-10-27 and due to reach its primary completion in 2024-07-23. Interventions recorded: IMC-001.
Shares ImmuneOncia Therapeutics and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.